RecruitingAtopic Dermatitis
Dupixent and Narrowband UVB for Atopic Dermatitis
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Sponsor: Psoriasis Treatment Center of Central New Jersey
You may qualify if…
- ✓ Male or female adult ≥ 18 years of age;
- ✓ Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
- ✓ EASI score of 16 or greater,
- ✓ IGA score of 3 or greater
- ✓ BSA of 10% or greater,
You may not qualify if…
- ✕ Subjects with previous exposure to dupilumab.
- ✕ Known or suspected hypersensitivity to dupilumab or any of its excipients.
- ✕ History of photosensitivity.
Where it's recruiting
New Jersey
East Windsor
Source: ClinicalTrials.gov · NCT05285839 · last updated 2024-03-15